Avinainder Singh, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyloid Neuropathies, Familial | 5 | 2018 | 134 | 1.910 |
Why?
|
| Myocardial Infarction | 27 | 2022 | 11403 | 1.780 |
Why?
|
| Registries | 22 | 2022 | 8048 | 1.020 |
Why?
|
| Amyloidosis | 6 | 2022 | 790 | 0.920 |
Why?
|
| Cardiovascular System | 2 | 2020 | 763 | 0.910 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2021 | 3149 | 0.910 |
Why?
|
| Heart Injuries | 2 | 2020 | 201 | 0.850 |
Why?
|
| Prealbumin | 4 | 2022 | 207 | 0.830 |
Why?
|
| Eligibility Determination | 1 | 2017 | 386 | 0.500 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 364 | 0.500 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2018 | 1005 | 0.360 |
Why?
|
| Cardiovascular Diseases | 8 | 2021 | 14438 | 0.330 |
Why?
|
| Coronary Artery Disease | 5 | 2020 | 6290 | 0.290 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2022 | 1514 | 0.290 |
Why?
|
| Atherosclerosis | 4 | 2021 | 3159 | 0.270 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2019 | 317 | 0.260 |
Why?
|
| Cardiomyopathies | 4 | 2022 | 1834 | 0.260 |
Why?
|
| Marijuana Abuse | 2 | 2018 | 387 | 0.260 |
Why?
|
| Heart Failure | 6 | 2022 | 10041 | 0.240 |
Why?
|
| Adenine | 3 | 2022 | 897 | 0.220 |
Why?
|
| Technetium | 2 | 2022 | 355 | 0.220 |
Why?
|
| Anterior Wall Myocardial Infarction | 1 | 2021 | 33 | 0.210 |
Why?
|
| Retrospective Studies | 22 | 2022 | 72473 | 0.210 |
Why?
|
| Heart Diseases | 3 | 2019 | 2754 | 0.200 |
Why?
|
| Young Adult | 13 | 2022 | 56228 | 0.200 |
Why?
|
| Middle Aged | 40 | 2022 | 214666 | 0.200 |
Why?
|
| Exercise Test | 2 | 2019 | 2110 | 0.200 |
Why?
|
| Humans | 61 | 2022 | 715818 | 0.200 |
Why?
|
| Lipoprotein(a) | 2 | 2021 | 394 | 0.190 |
Why?
|
| International Classification of Diseases | 3 | 2019 | 855 | 0.190 |
Why?
|
| Risk Factors | 18 | 2022 | 70879 | 0.190 |
Why?
|
| Coronary Angiography | 5 | 2020 | 4411 | 0.180 |
Why?
|
| Male | 42 | 2022 | 350352 | 0.180 |
Why?
|
| Myeloma Proteins | 1 | 2019 | 80 | 0.180 |
Why?
|
| Piperidines | 3 | 2022 | 1582 | 0.180 |
Why?
|
| Female | 43 | 2022 | 377229 | 0.170 |
Why?
|
| Hypoglycemic Agents | 3 | 2020 | 2774 | 0.170 |
Why?
|
| Age of Onset | 3 | 2021 | 3316 | 0.160 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 2361 | 0.160 |
Why?
|
| Health Services Misuse | 1 | 2019 | 242 | 0.150 |
Why?
|
| Patient Readmission | 3 | 2020 | 2980 | 0.150 |
Why?
|
| Prognosis | 12 | 2021 | 29007 | 0.150 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 240 | 0.150 |
Why?
|
| Neoplasm, Residual | 1 | 2021 | 986 | 0.150 |
Why?
|
| Drug Labeling | 1 | 2018 | 265 | 0.140 |
Why?
|
| Massachusetts | 5 | 2020 | 8743 | 0.140 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2017 | 164 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2019 | 318 | 0.140 |
Why?
|
| Hypolipidemic Agents | 1 | 2020 | 617 | 0.140 |
Why?
|
| United States Food and Drug Administration | 3 | 2020 | 1778 | 0.140 |
Why?
|
| Risk Assessment | 9 | 2021 | 23476 | 0.130 |
Why?
|
| Cholesterol | 2 | 2021 | 2866 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2020 | 1236 | 0.130 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 452 | 0.130 |
Why?
|
| Boston | 5 | 2019 | 9377 | 0.130 |
Why?
|
| Health Status Indicators | 1 | 2020 | 986 | 0.130 |
Why?
|
| Troponin | 1 | 2018 | 506 | 0.130 |
Why?
|
| Tendon Injuries | 1 | 2017 | 302 | 0.130 |
Why?
|
| Adult | 19 | 2022 | 212279 | 0.130 |
Why?
|
| Diabetic Angiopathies | 1 | 2019 | 846 | 0.120 |
Why?
|
| Radionuclide Imaging | 1 | 2018 | 2032 | 0.120 |
Why?
|
| Stroke Volume | 3 | 2021 | 4487 | 0.120 |
Why?
|
| Central Nervous System Diseases | 1 | 2018 | 530 | 0.120 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 1528 | 0.120 |
Why?
|
| Cocaine | 1 | 2018 | 994 | 0.120 |
Why?
|
| Heart | 2 | 2018 | 4315 | 0.120 |
Why?
|
| Aged | 22 | 2021 | 162468 | 0.120 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 3365 | 0.110 |
Why?
|
| United States | 14 | 2021 | 67910 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 11236 | 0.110 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2016 | 574 | 0.110 |
Why?
|
| Prevalence | 5 | 2021 | 14912 | 0.110 |
Why?
|
| Cohort Studies | 9 | 2022 | 40032 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1267 | 0.110 |
Why?
|
| Dyslipidemias | 1 | 2019 | 847 | 0.100 |
Why?
|
| Cyclophosphamide | 3 | 2022 | 2198 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2021 | 2144 | 0.100 |
Why?
|
| Coronary Stenosis | 1 | 2017 | 809 | 0.100 |
Why?
|
| Patient Discharge | 2 | 2020 | 3030 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 2222 | 0.100 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 58326 | 0.100 |
Why?
|
| Hospital Mortality | 5 | 2022 | 5141 | 0.090 |
Why?
|
| Recovery of Function | 1 | 2020 | 2929 | 0.090 |
Why?
|
| Vidarabine | 2 | 2021 | 348 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2019 | 1958 | 0.090 |
Why?
|
| Cause of Death | 4 | 2021 | 3612 | 0.090 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1687 | 0.090 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 421 | 0.090 |
Why?
|
| Smoking Cessation | 1 | 2020 | 2030 | 0.080 |
Why?
|
| Sex Factors | 2 | 2020 | 10666 | 0.080 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 1996 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2013 | 524 | 0.080 |
Why?
|
| Mortality | 4 | 2021 | 2837 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 15911 | 0.080 |
Why?
|
| Lipids | 1 | 2019 | 3242 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2019 | 2930 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2790 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 2263 | 0.070 |
Why?
|
| Treatment Outcome | 10 | 2022 | 62040 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2020 | 11090 | 0.070 |
Why?
|
| Comorbidity | 4 | 2021 | 10435 | 0.070 |
Why?
|
| Dementia | 1 | 2018 | 2258 | 0.070 |
Why?
|
| Thrombosis | 1 | 2019 | 2843 | 0.070 |
Why?
|
| Electrocardiography | 1 | 2019 | 6386 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2019 | 10503 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 5412 | 0.070 |
Why?
|
| Diabetes Mellitus | 2 | 2021 | 5463 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 2547 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2022 | 12460 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 2025 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2020 | 3268 | 0.070 |
Why?
|
| Time Factors | 4 | 2021 | 40887 | 0.060 |
Why?
|
| Echocardiography | 1 | 2016 | 5045 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2019 | 4095 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2019 | 4375 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 6730 | 0.060 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 4969 | 0.060 |
Why?
|
| Diphosphates | 1 | 2022 | 94 | 0.060 |
Why?
|
| Follow-Up Studies | 6 | 2020 | 39305 | 0.060 |
Why?
|
| Aspirin | 1 | 2014 | 3189 | 0.050 |
Why?
|
| Genotype | 1 | 2017 | 12919 | 0.050 |
Why?
|
| Age Factors | 4 | 2019 | 18787 | 0.050 |
Why?
|
| Research Design | 1 | 2017 | 5902 | 0.050 |
Why?
|
| Cardiac Electrophysiology | 1 | 2021 | 43 | 0.050 |
Why?
|
| Immunoglobulin Variable Region | 1 | 2022 | 419 | 0.050 |
Why?
|
| Survival Rate | 3 | 2021 | 13213 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2017 | 4279 | 0.050 |
Why?
|
| Product Labeling | 1 | 2020 | 86 | 0.040 |
Why?
|
| Phenotype | 1 | 2017 | 16311 | 0.040 |
Why?
|
| Knowledge | 1 | 2020 | 161 | 0.040 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2021 | 470 | 0.040 |
Why?
|
| Death Certificates | 1 | 2018 | 171 | 0.040 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2017 | 87 | 0.040 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2017 | 171 | 0.040 |
Why?
|
| Shock, Cardiogenic | 1 | 2022 | 599 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 6270 | 0.040 |
Why?
|
| Hospitalization | 3 | 2021 | 9745 | 0.040 |
Why?
|
| Myocardial Revascularization | 1 | 2021 | 847 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2017 | 351 | 0.040 |
Why?
|
| Rhabdomyolysis | 1 | 2018 | 157 | 0.040 |
Why?
|
| Economics, Hospital | 1 | 2018 | 199 | 0.040 |
Why?
|
| Paraproteinemias | 1 | 2019 | 247 | 0.040 |
Why?
|
| Hospitals | 2 | 2019 | 3375 | 0.040 |
Why?
|
| Incidence | 3 | 2021 | 20733 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 1968 | 0.040 |
Why?
|
| Public Opinion | 1 | 2020 | 467 | 0.040 |
Why?
|
| Thoracic Injuries | 1 | 2018 | 249 | 0.040 |
Why?
|
| Tobacco | 1 | 2018 | 418 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2021 | 866 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 946 | 0.030 |
Why?
|
| Arm | 1 | 2017 | 566 | 0.030 |
Why?
|
| Obesity | 1 | 2017 | 12248 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2019 | 929 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 495 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2021 | 1161 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2017 | 602 | 0.030 |
Why?
|
| Rubidium Radioisotopes | 1 | 2013 | 108 | 0.030 |
Why?
|
| Propensity Score | 1 | 2020 | 1762 | 0.030 |
Why?
|
| Chest Pain | 1 | 2020 | 1109 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2021 | 2512 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2020 | 1925 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 12483 | 0.030 |
Why?
|
| Amyloid | 1 | 2017 | 720 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2019 | 837 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2019 | 942 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2019 | 1236 | 0.030 |
Why?
|
| Age Distribution | 1 | 2018 | 2941 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2020 | 21795 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2016 | 1113 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 3543 | 0.020 |
Why?
|
| Perfusion | 1 | 2013 | 1273 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 2556 | 0.020 |
Why?
|
| Antibodies | 1 | 2017 | 2432 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2021 | 2497 | 0.020 |
Why?
|
| Acute Disease | 1 | 2019 | 7142 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2016 | 1069 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1825 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 7757 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2018 | 1738 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2016 | 4214 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3035 | 0.020 |
Why?
|
| Disease Progression | 1 | 2022 | 13215 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 4183 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2018 | 2361 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2019 | 6150 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 1842 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 7446 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2757 | 0.010 |
Why?
|
| African Americans | 1 | 2018 | 5003 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4282 | 0.010 |
Why?
|
| Smoking | 1 | 2020 | 8980 | 0.010 |
Why?
|
| Adolescent | 2 | 2021 | 85157 | 0.010 |
Why?
|
| Hypertension | 1 | 2021 | 8270 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 3015 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13623 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2014 | 9985 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 15198 | 0.010 |
Why?
|
| Myocardium | 1 | 2013 | 4909 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2022 | 41198 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2017 | 12535 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2013 | 13643 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 51317 | 0.010 |
Why?
|
| Inflammation | 1 | 2013 | 10082 | 0.010 |
Why?
|
| Animals | 1 | 2017 | 169404 | 0.000 |
Why?
|